Takeda sets sights on first-line lung cancer market with new Alunbrig dataPfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share XTakeda sets sights on first-line lung cancer market with new Alunbrig datahttps://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/
Experts concerned over mixed results from Takeda’s dengue vaccineTakeda’s dengue vaccine has met its target of protection against the disease in children – but there are Share XExperts concerned over mixed results from Takeda’s dengue vaccinehttps://pharmaphorum.com/news/experts-concerned-over-mixed-results-from-takedas-dengue-vaccine/
Takeda nets $660m from product selloff to Germany’s StadaTakeda has divested another block of products it views as lying outside its main focus, selling various drugs Share XTakeda nets $660m from product selloff to Germany’s Stadahttps://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/
Takeda buys coeliac drug licence from COUR PharmaceuticalsTakeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced Share XTakeda buys coeliac drug licence from COUR Pharmaceuticalshttps://pharmaphorum.com/news/takeda-buys-coeliac-drug-licence-from-cour-pharmaceuticals/
Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200mTakeda is to sell off a portfolio of over-the-counter and prescription drugs in the Near East, Middle East, Share XDebt-laden Takeda to sell OTC drugs in Middle East and Africa for $200mhttps://pharmaphorum.com/news/takeda-to-sell-otc-drugs-in-middle-east-and-africa-for-200m/
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techLA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that Share XImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techhttps://pharmaphorum.com/news/imaginab-joins-with-az-pfizer-and-takeda-to-develop-tumour-imaging-tech/
Takeda breaks into top 20 largest pharmas with Shire mergerTakeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger Share XTakeda breaks into top 20 largest pharmas with Shire mergerhttps://pharmaphorum.com/news/takeda-breaks-into-top-20-largest-pharmas-with-shire-merger/
Takeda eyes emerging markets asset sale to trim its debt; reportTakeda is said to be considering the sale of assets in emerging markets and western Europe to pay Share XTakeda eyes emerging markets asset sale to trim its debt; reporthttps://pharmaphorum.com/news/takeda-eyes-emerging-markets-asset-sale-to-trim-its-debt-report/
Evotec announces potential $850m R&D partnership with TakedaGermany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, Share XEvotec announces potential $850m R&D partnership with Takedahttps://pharmaphorum.com/news/evotec-announces-potential-850m-rd-partnership-with-takeda/
